Save the Date for ClinPGx/CPIC/PGRN 2025
The ClinPGx/CPIC 2025 Meeting will be held in collaboration with the PGRN in Missoula, Montana, September 8-11, 2025.
Topic
PharmGKB
A collection of 13 issues
New must-test alleles for DPYD
The recently published article DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics
Introducing the DDRx Mobile App!
Check out DDRx - the new mobile app for genotype-based prescribing guidance from PharmGKB/ClinPGx.
PharmGKB data now available in OpenTargets
Data from PharmGKB clinical annotations are now integrated into OpenTargets; a free online tool which brings together data from publicly available datasets to help prioritize potential drug targets.
The Pharmacogenetics section of the profile for both drugs and targets (genes) now shows information from PharmGKB clinical annotations, including the phenotype
ClinPGx 2024 Registration and Abstract Submission Open
REGISTRATION OPEN
In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation, including knowledgebases,
Release of Additional PharmGKB Pediatric Drug Summaries
A new round of PharmGKB's pediatric drug summaries is now available on PharmGKB under the Pediatric Focus.
To view the site with the focus active, please select the "Focus" button in the upper right-hand corner and toggle the "Pediatric Focus" setting.
Users can also
Disulfiram Pathway published in Pharmacogenetics and Genomics
Substance abuse disorders are a significant public health cost [PMID: 34453125]. Prescribers have limited choices for pharmaceutical therapies with only three FDA-approved choices for alcohol use disorder and zero for cocaine use disorder. Disulfiram is an FDA-approved treatment for alcohol use disorder which is also used for cocaine use disorder.
Update to PharmGKB Pediatric Summaries - BPCA Drugs
The latest round of PharmGKB’s pediatric drug summaries is now live on PharmGKB pediatric. This release includes summaries for 55 drugs, bringing the total summary count to over 180, now including all drugs on the Best Pharmaceuticals for Children Act (BPCA) priority list in addition to all CPIC guideline
Response to the American Academy of Pediatrics' Statement "Eliminating Race-Based Medicine"
On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate
Update to PharmGKB Pediatric Drug Summaries
The third round of PharmGKB's pediatric drug summaries is now live on PharmGKB pediatric. This release includes over 20 additional drugs with a focus on those on the Best Pharmaceuticals for Children Act (BPCA) priority list, including:
* Albendazole
* Amphotericin b
* Artesunate
* Atropine
* Baclofen
* Benznidazole
* Betamethasone
* Canakinumab
* Cefepime
* Ceftazidime